---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001157"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:21:19.698613+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix reports preliminary Q4 2021 revenue of $7.2M; core lung testing grows 49% YoY

## Summary
- Preliminary full-year 2021 total revenue of $54.5M, up from $45.6M in 2020.
- Core lung diagnostic testing revenue grew 49% for full-year 2021.
- Quarterly revenue excluding COVID-19 testing was $6.8M, up 22% YoY and 13% QoQ.
- Annual revenue excluding COVID-19 testing was $24.3M, up 41% YoY.
- Cash and cash equivalents as of Dec 31, 2021: $32.7M; exploring raising capital.

## SEC filing metadata
- accession: 0000950170-22-001157
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022001157/0000950170-22-001157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022001157/bdsx-20220214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001157
- JSON: https://secwatch.observer/filing/0000950170-22-001157.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.